enGene Therapeutics Inc. Common Stock (ENGN) is a publicly traded Healthcare sector company. As of July 16, 2026, ENGN trades at $1.93 with a market cap of $126.95M and a P/E ratio of 0.83. ENGN moved +0.00% today. Year to date, ENGN is -78.96%; over the trailing twelve months it is -45.87%. Its 52-week range spans $1.40 to $12.25. Analyst consensus is neutral with an average price target of $5.64. Rallies surfaces ENGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ENGN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.93 |
| Market Cap | $126.95M |
| P/E Ratio | 0.83 |
| EPS | $2.29 |
| Dividend Yield | 0.13% |
| 52-Week High | $12.25 |
| 52-Week Low | $1.40 |
| Volume | 498.30K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-117.30M |
| Gross Margin | 0.00% |
10 analysts cover ENGN: 0 strong buy, 3 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $5.64.